Emergent Biosolutions Inc (EBS) Gross Profit Margin starting from the third quarter 2026 to third quarter 2025, Profitability Trends and Ranking, Fundamental Ratios - CSIMarket
CSIMarket Company Name, Ticker, Industry, else..
 


• Gross Margin
• EBITDA Margin
• Operating Margin
• Net Margin
• Pre-Tax Margin
• Effective Tax Rate
• Free Cash Flow Margin
• Cash Flow Margin
Emergent Biosolutions Inc   (NYSE: EBS)


Emergent Biosolutions Inc 's Gross Profit Margin by quarter

Trends, Rankings, Statistics


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

EBS Gross Profit Margin (Sep 30 2026)
Q3 		(Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Revenue Change -52.4 %
Seq. Revenue Change -53.05 %
Revenue In Millions $110.00
Gross Profit Margin 26.55 %
Gross Profit Margin Total Ranking # 1582
Gross Profit In Millions $29.20
Y / Y Gross Profit Change -79.89 %
Seq. Gross Profit Change -78.72 %


Commenting Third Quarter 2026 Gross Profit Margin
Emergent Biosolutions Inc experienced contraction in Gross Profit by -78.72 % to $110 millions and Revenue by -53.05 %, while Gross Profit Margin fell to 26.55 %, below company*s average Gross Profit Margin.


Observing third quarter 2026 results within Major Pharmaceutical Preparations industry 107 other companies have achieved higher Gross Profit Margin. While Gross Profit Margin total ranking has impoved so far to 1582, from total ranking in the previous quarter at 2158.
Learn about Gross Margin
EBS's Gross Profit Margin third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 108
Healthcare Sector # 291
Overall # 1570

Gross Profit Margin Statistics
High Average Low
86.07 % 59.21 % 4.14 %
(Mar 31 2015)   (Dec 31 2018)


EBS Gross Income Trends • More of EBS's Profitabilty Ratios • EBS Stock Quotes and Charts


Other Gross Profit Margin Profitability Ratios
EBS's Cumulative Gross Profit Margin
Major Pharmaceutical Preparations Industry Gross Profit Margin Trends and Statistics
Healthcare Sector Gross Profit Margin Statistics
Gross Profit Margin Profitability Trends for overall market
EBS's Gross Profit Margin Profitability versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Gross Profit Margin
Lowest Ranking Gross Profit Margin
Gross Profit Margin Profit Margin for EBS's Competitors
Gross Profit Margin Profit Margin for Emergent Biosolutions Inc 's Suppliers
Gross Profit Margin Profit Margin for EBS's Customers

You may also want to know
EBS's Annual Growth Rates EBS's Profitability Ratios EBS's Asset Turnover Ratio EBS's Dividend Growth
EBS's Roe EBS's Valuation Ratios EBS's Financial Strength Ratios EBS's Gross Profit Growth
EBS's Roa EBS's Inventory Turnover Ratio EBS's Growth Rates EBS's Dividend Comparisons


Companies with similar Gross Profit Margin in the quarter ending Sep 30 2026, within Major Pharmaceutical Preparations Industry Gross Profit MarginSep 30 2026 MRQ Gross ProfitSep 30 2026 MRQ Revenue
Merck and Co Inc   72.95 %$ 13,193.000  Millions$ 18,085.000  Millions
Nature s Sunshine Products inc   72.86 %$ 84.962  Millions$ 116.603  Millions
Puma Biotechnology Inc   72.40 %$ 39.858  Millions$ 55.056  Millions
Clene Inc   71.43 %$ 0.040  Millions$ 0.056  Millions
IMPACT BIOMEDICAL INC.  71.43 %$ 0.015  Millions$ 0.021  Millions
Zoetis Inc   70.81 %$ 1,693.000  Millions$ 2,391.000  Millions
Harmony Biosciences Holdings inc   70.00 %$ 188.231  Millions$ 268.917  Millions
Earth Science Tech Inc   69.35 %$ 5.062  Millions$ 7.300  Millions
Bristol myers Squibb Company  68.28 %$ 8,923.000  Millions$ 13,069.000  Millions
Johnson and Johnson  68.12 %$ 17,302.000  Millions$ 25,399.000  Millions
Vera Therapeutics Inc   67.93 %$ 6.981  Millions$ 10.277  Millions
Evolus Inc   65.02 %$ 50.686  Millions$ 77.952  Millions
Opko Health Inc   64.30 %$ 42.063  Millions$ 65.414  Millions
Ani Pharmaceuticals Inc  61.64 %$ 179.246  Millions$ 290.777  Millions
Zomedica Corp   61.06 %$ 6.044  Millions$ 9.899  Millions
Schrodinger Inc   59.32 %$ 38.253  Millions$ 64.491  Millions
Abeona Therapeutics Inc   57.65 %$ 7.778  Millions$ 13.491  Millions
Elanco Animal Health Incorporated  56.92 %$ 720.000  Millions$ 1,265.000  Millions
Abbott Laboratories  56.75 %$ 7,385.000  Millions$ 13,013.000  Millions
Siga Technologies Inc  56.29 %$ 0.741  Millions$ 1.317  Millions
Teva Pharmaceutical Industries Limited  55.52 %$ 2,440.000  Millions$ 4,395.000  Millions
Organon and Co   55.21 %$ 869.000  Millions$ 1,574.000  Millions
Zai Lab Limited  52.59 %$ 56.903  Millions$ 108.208  Millions
Aquestive Therapeutics Inc   52.28 %$ 3.951  Millions$ 7.557  Millions
Prestige Consumer Healthcare Inc   51.30 %$ 172.538  Millions$ 336.307  Millions
Bausch Health Companies Inc   50.02 %$ 1,471.000  Millions$ 2,941.000  Millions
Amphastar Pharmaceuticals Inc   47.99 %$ 99.629  Millions$ 207.608  Millions
Cryoport inc   47.46 %$ 23.834  Millions$ 50.220  Millions
Collegium Pharmaceutical Inc   41.53 %$ 89.843  Millions$ 216.339  Millions
Amarin Corp Plcuk  40.66 %$ 16.181  Millions$ 39.799  Millions




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.